Valuation: HighTide Therapeutics, Inc.

Market Cap 1.53B 1.8B 230M 204M 189M 171M 322M 21.7B 327M 2.27B 889M 11.4B 862M 844M 36.32B P/E 2024
-1.41x
P/E 2025 -5.19x
Enterprise Value 1.16B 1.36B 173M 154M 143M 129M 243M 16.37B 247M 1.71B 671M 8.6B 650M 637M 27.41B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
63.21%
Yield 2024 *
-
Yield 2025 -
1 week+0.96%
Current month-8.30%
1 month-4.55%
3 months+19.77%
6 months-17.97%
Current year+6.78%
1 week 3
Extreme 3
3.16
1 month 3
Extreme 3
3.66
Current year 1.8
Extreme 1.8
4.72
1 year 1.8
Extreme 1.8
4.72
3 years 0.72
Extreme 0.72
13.18
5 years 0.72
Extreme 0.72
13.18
10 years 0.72
Extreme 0.72
13.18
Manager TitleAgeSince
Chief Executive Officer 56 01/01/2011
Director of Finance/CFO 57 01/12/2022
Chief Tech/Sci/R&D Officer - 02/02/2026
Director TitleAgeSince
Chairman 56 -
Director/Board Member 44 15/05/2023
Director/Board Member 68 30/11/2020
Date Insider Type Main position Quantity % Market Cap. Importance
4/30/26 A Other

Director

1,800,000 0.3151%
4/1/26 A Other

Chief Executive Officer

8,325,618 1.4572%
4/1/25 A Other

Chief Executive Officer

3,960,550 0.7694%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+0.96%-24.64% - 229M
-0.21%-6.36%+49.00%+74.13% 66.34B
-0.22%+10.10%+12.77%+87.32% 52.92B
+0.82%+9.46%+7.75%+73.53% 54.82B
+3.28%+6.12%+30.46%+50.05% 44.09B
+0.51%+10.71%+21.30%+133.92% 43.72B
-1.15%+3.10%+259.71%+594.60% 42.13B
+0.10%+9.96%+17.15%+59.33% 33.96B
-1.30%-3.61%+37.37%+7.16% 26.17B
+0.69%+6.07%+31.89%+26.94% 23.37B
Average +0.25%+4.49%+44.28%+123.00% 38.77B
Weighted average by Cap. +0.32%+4.67%+51.24%+127.77%

Financials

2024 2025
Net sales - -
Net income -382M -449M -57.28M -50.9M -47.11M -42.69M -80.29M -5.41B -81.52M -565M -222M -2.84B -215M -210M -9.06B -245M -288M -36.75M -32.66M -30.23M -27.39M -51.52M -3.47B -52.3M -363M -142M -1.82B -138M -135M -5.81B
Net Debt -413M -486M -61.93M -55.03M -50.93M -46.15M -86.81M -5.85B -88.14M -611M -240M -3.07B -232M -227M -9.79B -376M -443M -56.41M -50.12M -46.39M -42.04M -79.07M -5.33B -80.27M -556M -218M -2.8B -212M -207M -8.92B
Projected Income Statement - Annual - HighTide Therapeutics, Inc.
Logo HighTide Therapeutics, Inc.
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The Company has developed a product pipeline of multiple product candidates in-house, covering many indications in metabolic and digestive diseases among which, some are at clinical-stage. The Company’s core product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases. The Company conducts operations in the United States, Mainland China, Hong Kong and Australia.
Employees
55
Date Price Change Volume
21/10/26 HK$3.150 0.00% 273,000
20/10/26 HK$3.150 +1.78% 382,000
16/10/26 HK$3.095 +3.17% 178,500
15/10/26 HK$3.000 -2.91% 68,000
14/10/26 HK$3.090 -0.96% 220,500

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - HighTide Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. 2511 Stock